Law360, New York (June 10, 2009, 12:00 AM EDT) -- AstraZeneca PLC antipsychotic Seroquel, which had sales of $800 million in the U.S. in the first quarter of 2009, is acceptably safe and effective for treating schizophrenia in teenagers, as well as treating bipolar mania in kids as young as 10, according to a U.S. Food and Drug Administration panel.
The advisory committee weighed in Wednesday on Seroquel, as well as Eli Lilly and Co.'s Zyprexa and Pfizer Inc.'s Geodon.
In a 17-1 vote, the panel said that Seroquel was effective for treating schizophrenia in pediatric...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.